Benefit-risk assessment of traditional Chinese medicine preparations of sinomenine using multicriteria decision analysis (MCDA) for patients with rheumatoid arthritis

被引：0
|
作者：
Gao Xiang
Min Gao
Huirong Qin
Xiaolan Shen
Huilian Huang
Xiaoqiang Hou
Zhitao Feng
机构：
[1] China Three Gorges University,The First College of Clinical Medical Sciences
[2] Yichuan Community Health Service Center,Third
[3] Affiliated Renhe Hospital of China Three Gorges University,Grade Pharmacological Laboratory On Chinese Medicine Approved By State Administration of Traditional Chinese Medicine
[4] Institute of Rheumatology,undefined
[5] the First College of Clinical Medical Sciences,undefined
[6] China Three Gorges University,undefined
[7] Medical College of China Three Gorges University,undefined
来源：
BMC Complementary Medicine and Therapies | / 23卷
关键词：
Sinomenine; Traditional Chinese medicine; Rheumatoid arthritis; Benefit-risk assessment; Multicriteria decision analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Benefit-risk assessment of traditional Chinese medicine preparations of sinomenine using multicriteria decision analysis (MCDA) for patients with rheumatoid arthritis
    Xiang, Gao
    Gao, Min
    Qin, Huirong
    Shen, Xiaolan
    Huang, Huilian
    Hou, Xiaoqiang
    Feng, Zhitao
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2023, 23 (01)
  • [2] A simple way to unify multicriteria decision analysis (MCDA) and stochastic multicriteria acceptability analysis (SMAA) using a Dirichlet distribution in benefit-risk assessment
    Saint-Hilary, Gaelle
    Cadour, Stephanie
    Robert, Veronique
    Gasparini, Mauro
    BIOMETRICAL JOURNAL, 2017, 59 (03) : 567 - 578
  • [3] Comprehensive Benefit-Risk Assessment of Noninferior Treatments Using Multicriteria Decision Analysis
    Sidi, Yulia
    Harel, Ofer
    VALUE IN HEALTH, 2020, 23 (12) : 1622 - 1629
  • [4] Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis
    Ted R. Mikuls
    Larry W. Moreland
    Drug Safety, 2003, 26 : 23 - 32
  • [5] A benefit-risk assessment model for statins using multicriteria decision analysis based on a discrete choice experiment in Korean patients
    Byun, Ji-Hye
    Kwon, Sun-Hong
    Ha, Ji-Hye
    Lee, Eui-Kyung
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 965 - 974
  • [6] Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis
    Vermersch, Patrick
    Martinelli, Vittorio
    Pfleger, Claudia
    Rieckmann, Peter
    Alonso-Magdalena, Lucia
    Galazka, Andrew
    Dangond, Fernando
    Phillips, Lawrence
    CLINICAL THERAPEUTICS, 2019, 41 (02) : 249 - 260
  • [7] Benefit-Risk Assessment of Chinese Medicine Injections for Primary Liver Cancer Based on Multi-criteria Decision Analysis
    Zhang, Rong-rong
    Shao, Ming-yi
    Fu, Yu
    Zhao, Rui-xia
    Wnag, Jing-wen
    Fang, Yu-xuan
    CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2024, 30 (06) : 559 - 564
  • [8] Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
    Conaghan, Philip
    Cohen, Stanley
    Burmester, Gerd
    Mysler, Eduardo
    Nash, Peter
    Tanaka, Yoshiya
    Rigby, William
    Patel, Jayeshkumar
    Shaw, Tim
    Betts, Keith A.
    Patel, Pankaj
    Liu, Jianzhong
    Sun, Rochelle
    Fleischmann, Roy
    RHEUMATOLOGY AND THERAPY, 2022, 9 (01) : 191 - 206
  • [9] Benefit-Risk Assessment of LeflunomideAn Appraisal of Leflunomide in Rheumatoid Arthritis 10 Years After Licensing
    Nicola Alcorn
    Sarah Saunders
    Rajan Madhok
    Drug Safety, 2009, 32 : 1123 - 1134
  • [10] A network-based analysis of traditional Chinese medicine cold and hot patterns in rheumatoid arthritis
    Chen, Gao
    Lu, Cheng
    Zha, Qinglin
    Xiao, Cheng
    Xu, Shijie
    Ju, Dahong
    Zhou, Youwen
    Jia, Wei
    Lu, Aiping
    COMPLEMENTARY THERAPIES IN MEDICINE, 2012, 20 (1-2) : 23 - 30
12345